First National Bank of Omaha decreased its position in Allergan PLC (NYSE:AGN) by 1.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,888 shares of the company’s stock after selling 969 shares during the period. Allergan PLC comprises approximately 0.9% of First National Bank of Omaha’s holdings, making the stock its 28th largest position. First National Bank of Omaha’s holdings in Allergan PLC were worth $11,950,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of AGN. Barnett & Company Inc. bought a new position in shares of Allergan PLC during the first quarter valued at about $111,000. Livingston Group Asset Management CO operating as Southport Capital Management purchased a new stake in shares of Allergan PLC during the second quarter valued at $125,000. Trust Co. of Vermont boosted its stake in shares of Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares in the last quarter. Carroll Financial Associates Inc. boosted its stake in shares of Allergan PLC by 68.7% in the third quarter. Carroll Financial Associates Inc. now owns 555 shares of the company’s stock valued at $127,000 after buying an additional 226 shares in the last quarter. Finally, Integrated Investment Consultants LLC boosted its stake in shares of Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares in the last quarter. Hedge funds and other institutional investors own 89.21% of the company’s stock.

Institutional Ownership by Quarter for Allergan PLC (NYSE:AGN)

Allergan PLC (NYSE:AGN) traded down 0.45% during midday trading on Friday, reaching $192.22. The company had a trading volume of 1,224,595 shares. The stock’s 50 day moving average is $212.72 and its 200 day moving average is $233.35. The firm has a market capitalization of $72.10 billion, a price-to-earnings ratio of 5.39 and a beta of 1.08. Allergan PLC has a 12-month low of $184.50 and a 12-month high of $322.68.

Allergan PLC (NYSE:AGN) last released its quarterly earnings data on Wednesday, November 2nd. The company reported $3.32 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.65 by $0.33. The firm had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.73 billion. Allergan PLC had a net margin of 93.74% and a return on equity of 7.26%. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.48 EPS. Equities research analysts expect that Allergan PLC will post $13.37 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 28th. Stockholders of record on Tuesday, February 28th will be issued a dividend of $0.70 per share. This is an increase from Allergan PLC’s previous quarterly dividend of $0.05. This represents a $2.80 annualized dividend and a dividend yield of 1.46%.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2016/11/27/first-national-bank-of-omaha-sells-969-shares-of-allergan-plc-agn.html.

Several brokerages have weighed in on AGN. William Blair reissued a “market perform” rating on shares of Allergan PLC in a report on Monday, November 21st. Mizuho dropped their price objective on Allergan PLC from $293.00 to $273.00 and set a “buy” rating for the company in a report on Thursday, November 17th. Vetr cut Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $235.38 price objective for the company. in a report on Wednesday, November 9th. RBC Capital Markets reissued an “outperform” rating and set a $279.00 price objective (down from $300.00) on shares of Allergan PLC in a report on Thursday, November 3rd. Finally, Morgan Stanley dropped their price objective on Allergan PLC from $300.00 to $274.00 and set an “overweight” rating for the company in a report on Thursday, November 3rd. Seven research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $289.11.

In other news, CEO Brent L. Saunders acquired 5,250 shares of the firm’s stock in a transaction dated Monday, November 21st. The stock was purchased at an average price of $189.13 per share, for a total transaction of $992,932.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Maria Teresa Hilado acquired 1,422 shares of the firm’s stock in a transaction dated Friday, November 11th. The shares were purchased at an average price of $210.64 per share, with a total value of $299,530.08. Following the acquisition, the chief financial officer now owns 12,659 shares of the company’s stock, valued at $2,666,491.76. The disclosure for this purchase can be found here. Insiders own 0.27% of the company’s stock.

About Allergan PLC

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.